LongeVC | News, Hiring, Layoffs, Competitors, CEO, Fundraising Insights

---

LongeVC is a venture capital firm based in Lugano, Switzerland, founded in 2016. The company specializes in supporting early-stage biotech and longevity-focused founders, helping them gain industrial momentum, raise capital, and shape the future of the biotech industry. LongeVC aims to build a broad community of biotech innovators by funding companies in complementary sectors and facilitating collaboration among them.

🛍️ LongeVC Product and Pricing News →

👔 LongeVC CEO, Management and Leadership Team →

⚔️ LongeVC Alternatives and Competitors →

💼 LongeVC Hiring and Layoffs →

🤖 LongeVC Developer, Integration and Automation News →

📈 LongeVC Financials, Fundraising and Valuation News →

---

🛍️ LongeVC Product and Pricing News

• Sergey Jakimov, co-founder and partner at LongeVC, emphasizes a pragmatic, disease-driven approach to longevity by investing in treatments for age-related conditions like cancer and neurodegenerative diseases.
• Rubedo Life Sciences, a portfolio company of LongeVC, announced plans for a Phase 1 clinical trial of their GPX4 modulator RLS-1496 targeting aging cells.
• LongeVC will participate as a sponsor in the Longevity Science Summit in Miami, aiming to raise $250K for longevity research projects.
• Garri Zmudze of LongeVC participated in an investors panel at ARDD2024 discussing the development of the longevity biotechnology industry.
• Sergey Jakimov, co-founder of LongeVC, emphasizes the company's focus on investing in innovative biotech and healthcare solutions to improve health spans and support early-stage companies in longevity science.

• LongeVC's portfolio company CatenaBio, based in Berkeley's Bakar Labs, was featured among Berkeley's top 10 startups to watch in 2025 for its innovative CysTyr™ platform and Multi-Payload Conjugates technology.
• LongeVC's co-founders Sergey Jakimov and Ilya Suharenko will participate in the Unicorn Summit in Lisbon, Portugal from June 29 to July 2, 2025.
• Sergey Jakimov, Founding Partner at LongeVC, discusses how Europe can enhance biotech success through IP commercialization and incentivization in his op-ed for EU VC.

---

👔 LongeVC CEO, Management and Leadership Team

• Konstantinos Maitos

  
  Chief Financial Officer
  [email protected]

---

⚔️ LongeVC Alternatives and Competitors

• Aeravti Ventures
|
• Black Diamond Ventures

---

💼 LongeVC Hiring and Layoffs

• Hyeyoung Eléonore S. has joined LongeVC as a Venture Scout in Norway.
• Krishna Amin has joined LongeVC as a Venture Scout.

---

🤖 LongeVC Developer, Integration and Automation News

• LongeVC's portfolio company Longenesis has partnered with Novartis Baltics on a pilot project to transform cardiovascular disease treatment and prevention in Latvia.
• Unnatural Products Inc., a LongeVC portfolio company, is pioneering AI-powered macrocyclic molecule design in collaboration with Merck to enhance drug discovery for complex diseases.
• LongeVC's portfolio company Longenesis has partnered with Novartis Baltics and Daugavpils Regional Hospital to launch a pilot project for cardiovascular disease treatment and prevention in Latvia.

---

📈 LongeVC Financials, Fundraising and Valuation News

• LongeVC's portfolio company Melio, led by Mridu Sinha, received a $3.5M grant to develop a platform for rapid identification of bloodstream infections, starting with neonatal sepsis.
• LongeVC participated in Proton Intelligence Inc.'s $6.95 million seed financing round for their Continuous Potassium Monitoring platform.
• LongeVC has invested in Proton Intelligence, a company developing the first minimally invasive continuous potassium monitoring devices to improve management of chronic conditions.
• LongeVC has invested in Glyphic Biotechnologies, which is developing single-molecule protein sequencing technology.
• LongeVC's comparative indices for 2023 show slight improvements in net turnover, equity capital, fixed assets, balance, tangible assets, and liquidity.

• LongeVC's comparative indices for 2023 show slight improvements in net turnover, profit or loss, equity capital, fixed assets, balance, tangible assets, and liquidity.
• Artem Trotsyuk, operating partner at LongeVC, noted a trend of larger companies acquiring smaller biotechs to access new medicines and technologies.

---

People also viewed

• Beamline Accelerator
|
• Outlast Fund
|
• Tesonet
|
• NGL
|
• UniTartu Ventures
|
• Honey Badger Capital
|
• Taavet+Sten
|
• theIntelligent VC
|
• Inventure
|
• Nordic Secondary Fund
|
• Vendep Capital
|
• Fiedler Capital